Investigational drug · Phase 3
Toludesvenlafaxine Hydrochloride Sustained-release
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Generalized Anxiety Disorder.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "Toludesvenlafaxine Hydrochloride Sustained-release"
First trial start
2023
Aug 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Toludesvenlafaxine Hydrochloride Sustained-release", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Toludesvenlafaxine Hydrochloride Sustained-release" as an intervention, largest first.
- To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release TabletsPivotal-lookingNot yet recruiting
Luye Pharma Group Ltd.Industry
NCT06426485 · 736 participants (planned) · Start May 30, 2024 · Primary completion Feb 28, 2027
Drug: Toludesvenlafaxine Hydrochloride Sustained-release Tablets; placebo · For: Major Depressive Disorder
- A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.Pivotal-lookingCompleted
Luye Pharma Group Ltd.Industry
NCT05970510 · 555 participants · Start Aug 4, 2023 · Primary completion Jul 31, 2025
Drug: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg; Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg and 1 more · For: Generalized Anxiety Disorder
Sites: Beijing, China
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT06278038 · 84 participants · Start Feb 22, 2024 · Primary completion Nov 10, 2024
Drug: Toludesvenlafaxine hydrochloride sustained-release tablets; Venlafaxine hydrochloride sustained-release tablets · For: Major Depression Disorder
Sites: Hangzhou, China
Jiangsu Province Nanjing Brain HospitalAcademic, hospital or other
NCT06270433 · 80 participants (planned) · Start Feb 19, 2024 · Primary completion Dec 31, 2024
Drug: Toludesvenlafaxine hydrochloride sustained-release tablets; Desvenlafaxine succinate sustained-release tablets · For: Anhedonia
Sites: Nanjing, China
Shanghai Mental Health CenterAcademic, hospital or other
NCT05849272 · 60 participants · Start May 12, 2023 · Primary completion May 8, 2024
Drug: toludesvenlafaxine hydrochloride sustained-release tablets · For: Somatic Symptom
Sites: Shanghai, China
Shanghai Mental Health CenterAcademic, hospital or other
NCT06026917 · 15 participants (planned) · Start Sep 25, 2023 · Primary completion Jan 31, 2024
Drug: Toludesvenlafaxine hydrochloride sustained-release tablets · For: Major Depressive Disorder
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in depression with ineffective or partially effective initial antidepressant treatment: a single-arm, multicenter clinical study.
Yang J, Jia Y, Chen K, et al. · Front Psychiatry 2025
- Efficacy and safety of Toludesvenlafaxine extended-release tablets in the treatment of treatment-resistant depression.
Qi Z, Xiaowen G, Wenjie L, et al. · BMC Psychiatry 2025
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets on Somatic Symptoms of Major Depressive Disorder: A Prospective, Single-Arm, Multicenter Clinical Study.
Wang Y, He M, Zhang H, et al. · Neuropsychiatr Dis Treat 2025
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets in Depression With Anhedonia: A Single-Arm, Multicenter Clinical Study.
Wang SW, Mi WF, Hao XN, et al. · Depress Anxiety 2025
- PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans.
Huang Z, Wu J, Guan Y, et al. · Eur J Nucl Med Mol Imaging 2024
Also in development for Generalized Anxiety Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- BuagafuranPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.